
BPC-157 FDA status in 2026: Compounding and legality

As of 2026, BPC-157, CJC-1295, and ipamorelin are not FDA-approved drugs, and all appear on the FDA’s Section 503A “Category 2” list (FDA Category 2 list, accessed February 15, 2026). Thymosin beta-4, which is often marketed online under the nickname “TB-500,” also appears on the FDA’s Section 503A “Category 2” list (FDA Category 2 list, ...




